In addition, FDA agreed to submit to the district court and to the NRDC status reports every 6 months (until each monograph is completed) containing a description of the actions taken by FDA to meet ...
On Thursday the Food and Drug Administration announced it is proposing to remove oral phenylephrine as an active ingredient that can be used in over-the-counter monograph drug products for the ...
SILVER SPRING, Md., Nov. 7, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration announced it is proposing to remove oral phenylephrine as an active ingredient that can be used in ...
위드카뉴스 on MSN
dsm-firmenich welcomes FDA proposal to expand US sunscreen actives, paving the way for PARSOL Shield
This proposal marks a historic milestone as it follows the first-ever Tier 1 OTC Monograph Order Request (OMOR) to be submitted to FDA – by dsm-firmenich - to amend OTC Monograph M020 and permit PARSO ...
Based on the data reviewed by the FDA, bemotrizinol provides protection against both ultraviolet A and B rays, has low levels ...
The FDA committee unanimously concluded the data do not support oral phenylephrine’s effectiveness as a nasal decongestant. The Food and Drug Administration (FDA) announced a proposal to remove oral ...
Hosted on MSN
FDA proposes allowing new sunscreen ingredient
The FDA has proposed adding bemotrizinol as a new active ingredient allowed in sunscreens, in a move it says will "advance sunscreen innovation." This move is part of a broader initiative in the ...
The FDA is urging lawmakers to reauthorize a key user fee program that could expand access to over the counter medications, reducing barriers to treatment. At a recent hearing before the Senate Health ...
Sunscreens in the United States might soon be able to include a new ingredient.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback